Free shipping on all orders over $ 500

XL413

Cat. No. M3641

XL413 Structure

Synonym: BMS-863233

Size Price Availability Quantity
10mg USD 200 In stock
50mg USD 600 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

XL413 inhibits the cell proliferation. XL413 decreases cell viability and elicits the caspase 3/7 activity in Colo-205 cells. XL413 results in modified S phase progression that subsequently leads to apoptotic cell death. XL413, at the 3 mg/kg dose, causes 70% inhibition of phosphorylated MCM2, and causes significant tumor growth regression at the 100 mg/kg dose.

Protocol
Cell Experiment
Cell lines Colo-205 cells
Preparation method Using BrdU incorporation assay to measure the cell proliferation , and by Cell Titer–Glo kits to assay viability .
Concentrations ~10 μM
Incubation time 24 hours
Animal Experiment
Animal models Mice bearing Colo-205 xenografts
Formulation
Dosages ~100 mg/kg
Administration p.o.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 326.18
Formula C14H13Cl2N3O2
CAS Number 1169562-71-3
Purity >99%
Solubility DMSO
Storage at -20°C
References

Discovery of XL413, a potent and selective CDC7 inhibitor.
Koltun ES, et al. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31. PMID: 22560567.

Related CDK Products
NU2058

NU2058 is a guanine-based CDK inhibitor with IC50 of 17 μM and 26 μM for CDK2 and CDK1.

LDC000067

LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.

RO-3306

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

LDC4297

LDC4297 is a novel CDK7 inhibitor (IC50=0.13±0.06 nM for CDK7 versus IC50s between 10 nM and 10,000 nM for all other analyzed CDKs).

THZ1

THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: XL413, BMS-863233 supplier, CDK, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.